155 related articles for article (PubMed ID: 21480857)
1. Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.
Alexandroff AB; Shpadaruk V; Bamford WM; Kennedy DB; Burd R; Dyer MJ
Br J Haematol; 2011 Aug; 154(3):419-21. PubMed ID: 21480857
[No Abstract] [Full Text] [Related]
2. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
[TBL] [Abstract][Full Text] [Related]
4. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab in Sézary syndrome: efficient but not innocent.
Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
[TBL] [Abstract][Full Text] [Related]
6. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
Lundin J; Kennedy B; Dearden C; Dyer MJ; Osterborg A
Blood; 2005 May; 105(10):4148-9. PubMed ID: 15867423
[No Abstract] [Full Text] [Related]
7. Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?
Fernandes IC; Gonçalves M; dos Anjos Teixeira M; Gonçalves C; Coutinho J; Selores M; Alves R; Lima M
J Am Acad Dermatol; 2012 Nov; 67(5):1083-5. PubMed ID: 23062898
[No Abstract] [Full Text] [Related]
8. Alemtuzumab in refractory Sézary syndrome.
Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
Kennedy GA; Seymour JF; Wolf M; Januszewicz H; Davison J; McCormack C; Ryan G; Prince HM
Eur J Haematol; 2003 Oct; 71(4):250-6. PubMed ID: 12950233
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab as first- and second-line treatment in patients with Sézary syndrome-The experience of a tertiary centre.
Nogueira M; Lau C; Teixeira MDA; Peixeiro R; Cabral R; Fernandes I
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e86-e88. PubMed ID: 37595960
[No Abstract] [Full Text] [Related]
11. Alemtuzumab treatment for Sézary syndrome: A single-center experience.
Novelli S; García-Muret P; Sierra J; Briones J
J Dermatolog Treat; 2016; 27(2):179-81. PubMed ID: 26329989
[TBL] [Abstract][Full Text] [Related]
12. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy.
Bolli N; Di Ianni M; Simonetti S; Cerroni L; Liso A; Falini B; Tabilio A
Lancet Oncol; 2004 Jan; 5(1):64-5. PubMed ID: 14700612
[No Abstract] [Full Text] [Related]
13. Pulmonary cryptococcoma in a patient with Sézary syndrome treated with alemtuzumab.
Hotz C; Ingen-Housz-Oro S; Tran Van Nhieu J; Charlier C; Foulet F; Rahmouni A; Zegai B; Duong TA; Wolkenstein P; Bagot M; Chosidow O
Eur J Dermatol; 2011; 21(6):1018-20. PubMed ID: 21926045
[No Abstract] [Full Text] [Related]
14. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome.
Jawed SI; Busam K; Wang X; Horwitz S; Querfeld C
JAMA Dermatol; 2014 Sep; 150(9):1021-3. PubMed ID: 25029560
[No Abstract] [Full Text] [Related]
16. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
Grey M
Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
[No Abstract] [Full Text] [Related]
17. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
Lenihan DJ; Alencar AJ; Yang D; Kurzrock R; Keating MJ; Duvic M
Blood; 2004 Aug; 104(3):655-8. PubMed ID: 15073032
[TBL] [Abstract][Full Text] [Related]
18. Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.
Roch N; Salameire D; Gressin R; Morand P; Epaulard O; Pavese P; Brion JP; Stahl JP
Scand J Infect Dis; 2008; 40(4):343-6. PubMed ID: 17934981
[TBL] [Abstract][Full Text] [Related]
19. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
Amengual JE; Raphael BG
Leuk Lymphoma; 2010 Jul; 51(7):1347-50. PubMed ID: 20572801
[No Abstract] [Full Text] [Related]
20. Successful treatment of refractory Sezary syndrome by anti-PD-1 antibody (nivolumab).
Shen K; Liu Y; Cao X; Zhou D; Li J
Ann Hematol; 2017 Apr; 96(4):687-688. PubMed ID: 28120019
[No Abstract] [Full Text] [Related]
[Next] [New Search]
